Sabril (SAY-bril, vigabatrin) is a new oral therapy for refractory epilepsy and infantile spasms

October 2009

Sabril (SAY-bril, vigabatrin) is a new oral therapy for refractory epilepsy and infantile spasms.

Use of this drug will be restricted because it can cause permanent vision loss in about 30% of patients.

This vision loss is a progressive narrowing of the visual field. The risk increases with higher doses or longer duration.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote